HEM Stock Overview
A clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Hemostemix Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.29 |
| 52 Week High | CA$0.42 |
| 52 Week Low | CA$0.035 |
| Beta | 0.18 |
| 1 Month Change | 136.00% |
| 3 Month Change | 227.78% |
| 1 Year Change | 195.00% |
| 3 Year Change | 110.71% |
| 5 Year Change | 47.50% |
| Change since IPO | -98.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| HEM | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -22.4% | 4.7% | -0.7% |
| 1Y | 195.0% | 12.6% | 16.9% |
Return vs Industry: HEM exceeded the Canadian Biotechs industry which returned 11.6% over the past year.
Return vs Market: HEM exceeded the Canadian Market which returned 16.9% over the past year.
Price Volatility
| HEM volatility | |
|---|---|
| HEM Average Weekly Movement | 35.7% |
| Biotechs Industry Average Movement | 13.8% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CA Market | 18.4% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: HEM's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: HEM's weekly volatility has increased from 29% to 36% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Thomas Smeenk | hemostemix.com |
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Hemostemix Inc. Fundamentals Summary
| HEM fundamental statistics | |
|---|---|
| Market cap | CA$40.79m |
| Earnings (TTM) | -CA$1.99m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-20.8x
P/E RatioIs HEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HEM income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$1.99m |
| Earnings | -CA$1.99m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.014 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -55.1% |
How did HEM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/04 13:02 |
| End of Day Share Price | 2025/02/04 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hemostemix Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Siddharth Rajeev | Fundamental Research Corp. |